Acadia Pharmaceuticals Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Acadia Pharmaceuticals Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 54.0 times. Higher than almost all Healthcare companies in United States.
- Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 96% of Healthcare companies in United States.
- Profit Cash Ratio: Over the last 3 years, every $100 of reported profit came with $51 of operating cash. Lower than 93% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
$51Over the last 3 years, every $100 of reported profit came with $51 of operating cash.
Lower than 93% of Healthcare companies in United States.
Self-Funding Ratio
54.0×Over the last 3 years its own operating cash covered its investment spending (capex) 54.0 times.
Higher than almost all Healthcare companies in United States.
Cash Locked Ratio
$16For every $100 of sales, $16 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $11 tied up three years earlier.
Less money tied up than 66% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
$110Sales grew 107% in 3 years; of every extra $100 of sales, $110 became extra profit.
Higher than 82% of Healthcare companies in United States.
Asset Productivity Ratio
+107% / +166%In 3 years sales changed by +107% while total assets changed by +166%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
9.4×Debt due within a year is covered 9.4 times by its yearly operating cash.
Higher than 84% of Healthcare companies in United States.
Cash Cushion Ratio
+22%Cash, after subtracting all debt, equals 22% of its market value (net cash).
Higher than 64% of Healthcare companies in United States.
Tangible Assets Ratio
93%Of every $100 the company owns, $93 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 67% of Healthcare companies in United States.
Tangible Net Worth Ratio
91%Of every $100 of net worth, $91 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 73% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Acadia Pharmaceuticals Inc. owes $0.25 for every $1 it owns. Net profit rose 73% in the year to Dec 2025.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
9.1Investors pay $9.1 for every $1 of Acadia Pharmaceuticals Inc.'s yearly profit, lower than 82% of Healthcare companies in United States.
P/B ratio
2.68The share price is 2.68 times Acadia Pharmaceuticals Inc.'s book value per share, higher than 52% of Healthcare companies in United States.
Market cap
$3.5 BThe total market value of all of Acadia Pharmaceuticals Inc.'s shares at today's price (share price × number of shares), larger than 81% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$1.3 BWhat Acadia Pharmaceuticals Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$7.58Net worth divided by the number of shares. The share price of $20.31 is 2.7 times this, which is the P/B above.
Return on equity (ROE)
35.7%Acadia Pharmaceuticals Inc. earned 35.7% on its shareholders' money over the last year, higher than 95% of Healthcare companies in United States.
Owes vs Owns
0.25×Acadia Pharmaceuticals Inc. owes $0.25 for every $1 it owns (low), lower than 66% of Healthcare companies in United States.
Dividend yield
NoneAcadia Pharmaceuticals Inc. does not currently pay a dividend.
Revenue growth
+12%Revenue rose 12% in the year to Dec 2025, and grew 27% a year on average over 3 years.
Profit growth
+73%Net profit rose 73% in the year to Dec 2025.
Profit margin
36.5%Acadia Pharmaceuticals Inc. keeps $36 of every $100 of revenue as net profit.
Cash quality
0.3×Cash from Acadia Pharmaceuticals Inc.'s business was 0.3× its reported profit in the year to Dec 2025 — less cash came in than the profit reported.
Cash vs debt
Net cashAcadia Pharmaceuticals Inc. held $767 M more cash than debt (net cash) at Dec 2025.
Questions
What is Acadia Pharmaceuticals Inc.'s P/E ratio?
Investors pay $9.1 for every $1 of Acadia Pharmaceuticals Inc.'s yearly profit, lower than 82% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Acadia Pharmaceuticals Inc.: $3.5 B ÷ $1.3 B (30 Jun 2026) = 2.7.
What is Acadia Pharmaceuticals Inc.'s return on equity?
Acadia Pharmaceuticals Inc. earned 35.7% on its shareholders' money over the last year, higher than 95% of Healthcare companies in United States.
How much does Acadia Pharmaceuticals Inc. owe compared with what it owns?
Acadia Pharmaceuticals Inc. owes $0.25 for every $1 it owns (low), lower than 66% of Healthcare companies in United States.
Does Acadia Pharmaceuticals Inc. pay a dividend?
No. Acadia Pharmaceuticals Inc. does not currently pay a dividend.
Is Acadia Pharmaceuticals Inc.'s revenue growing?
Revenue rose 12% in the year to Dec 2025, and grew 27% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.